A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Sponsor(s)

Array Biopharma

Principal Investigator(s)Jonathan L Kaufman, MD
Dates2/01/2011 - 2/28/2015